Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$356.40 USD

356.40
364,922

+13.51 (3.94%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JSMD

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

by Zacks Equity Research

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Medpace (MEDP) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 8.82% and 3.41%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

UnitedHealth Group's (UNH) Arm OptumRx Expands in Arizona

by Zacks Equity Research

UnitedHealth Group (UNH) is set to enhance the offerings of OptumRx with the recent expansion of pharmacy care services in Arizona.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi

by Zacks Equity Research

Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.

Are Medical Stocks Lagging Medpace (MEDP) This Year?

by Zacks Equity Research

Here is how Medpace (MEDP) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Fresenius Medical (FMS) Sinks on Potential Rise in Competition

by Zacks Equity Research

Fresenius Medical's (FMS) shares decline more than 17% on Wednesday following news of the successful clinical trial of a competing drug in preventing kidney disease.

NextGen's (NXGN) AI-Based Ambient Assist to Expedite Care Plans

by Zacks Equity Research

NextGen's (NXGN) Ambient Assist will help reduce significant time by summarizing appointments and preparing care plans using AI-driven technology in real time.

DexCom (DXCM) to Launch Latest CGM System G7 in Canada

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Growing Membership, expanding government business, strategic acquisitions, improving operating margin and solid 2024 plans poise UnitedHealth Group (UNH) well for growth.

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Here's Why Investors Should Retain Humana (HUM) Stock Now

by Zacks Equity Research

Humana (HUM) benefits from an upgraded health plan offering suite, expanding Medicare Advantage membership and solid cash reserves.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

by Zacks Equity Research

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.

Reasons to Add Stryker (SYK) Stock to Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

UnitedHealth Group (UNH) to Expand Coverage Area in 2024

by Zacks Equity Research

UnitedHealth Group (UNH) is set to enhance its offerings with UCard and expand to 110 new counties in 2024 with its Individual Medicare Advantage Plan.

Cardinal Health (CAH) Launches Next-Gen Enteral Feeding Pump

by Zacks Equity Research

Cardinal Health's (CAH) Kangaroo OMNI enteral feeding pump, with new portable design and effectiveness in terms of personalized care, is likely to improve the quality of life for patients.

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

UnitedHealth Group (UNH) Wins Medicaid Deal to Help Serve Texas

by Zacks Equity Research

UnitedHealth Group (UNH) unit has been awarded a contract by the Texas Health and Human Services Commission to better cater to the statewide Medicaid members.

Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.